Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary

Nagai, Yutaka; Inamine, Morihiko; Hirakawa, Makoto; Kamiyama, Kazuya; Ogawa, Kazuhiko; Toita, Takafumi; Murayama, Sadayuki; Aoki, Yoichi

doi:10.1016/j.ygyno.2007.07.079

Cited by 60 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At this point, there are no clearly superior alternatives to platinum-based chemotherapy. Recently, however, postoperative whole abdominal radiotherapy was shown to be effective in patients with stages Ic-III CCC as compared with a historical control group treated with platinum-based chemotherapy [79].…”

Section: Therapymentioning

confidence: 99%

Ovarian carcinoma pathology and genetics: recent advances

2009

View full text Add to dashboard Cite

Section: Therapymentioning

confidence: 99%

Ovarian carcinoma pathology and genetics: recent advances

2009

View full text Add to dashboard Cite

“…At this point there are no clearly superior alternatives to platinum-based chemotherapy. Recently, however, postoperative whole abdominal radiotherapy was shown to be effective in patients with stage Ic-III CC, compared to a historical control group treated with platinum-based chemotherapy [29].…”

Section: Clear Cell Carcinomas (Ccc)mentioning

confidence: 99%

Classification of ovarian carcinomas based on pathology and molecular genetics

D’Angelo

Prat

2010

Clin Transl Oncol

View full text Add to dashboard Cite

Malignant epithelial tumours (carcinomas) are the most common ovarian cancers and the most lethal gynaecological malignancies. Based on light microscopy and molecular genetics, ovarian carcinomas are subdivided into at least five main subtypes that account for over 95% of cases and are inherently different diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy and outcome. For successful subtype-specific treatment, reproducible pathological diagnosis of tumour cell type is critical. Recent investigations have also demonstrated that a significant number of cancers traditionally thought to be primary ovarian tumours (particularly serous, endometrioid and clear cell carcinomas) originate in the fallopian tube and the endometrium and involve the ovary secondarily. In this review we summarise recent advances in the molecular pathology, which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.

show abstract

“…Five-year OS and DFS in the WAR/HC group were 81.8%/33.3% and 81.2%/25.0% (p=0.031 and p=0.006), respectively. This study concluded that postoperative WAR may be effective in selected patients with ovarian clear cell carcinoma (Nagai et al, 2007).…”

Section: Radiotherapy In Non-serous Histologymentioning

confidence: 67%